Litcius/Paper detail

A light and hypoxia-activated nanodrug for cascade photodynamic-chemo cancer therapy

Yin Zhong, Si Huang, Chujie Zheng, Jinsheng Huang, Bo Li, Shisong Han, Hong Xiao, Yong Wang, Xintao Shuai

2021Biomaterials Science20 citationsDOI

Abstract

Combination therapy provides significantly better outcomes than a single drug treatment and becomes an efficient strategy for cancer therapy at present. Owing to the advantages of improved drug bioavailability, decreased side effects, and drug codelivery properties, polymeric carrier-based nanodrugs show great application potential in combination therapy. In this study, a pH-responsive block polymer consisting of polyethylene glycol (mPEG) and poly(asparagyl diisopropylethylenediamine-co-phenylalanine) (P(Asp(DIP)-co-Phe)) is synthesized for drug delivery. The polymer self-assembles into nanovesicles and simultaneously encapsulates the hydrophilic hypoxia-activated prodrug tirapazamine (TPZ) and the hydrophobic photosensitizer dihydrogen porphin (chlorin e6, Ce6). The formed nanodrug can be triggered by near infrared irradiation to induce photodynamic therapy (PDT), resulting in a hypoxic tumor environment to activate the prodrug TPZ to achieve efficient chemotherapy. The cascade synergistic therapeutic effect is evaluated both in vitro and in vivo in a breast cancer mice model. This study reveals a potential strategy for efficient cancer therapy by using Ce6 and TPZ co-encapsulated nanovesicles.

Topics & Concepts

TirapazaminePhotodynamic therapyHypoxia (environmental)Cancer therapyChemistryPhotosensitizerCancer researchTumor hypoxiaCancerPhotochemistryMedicineRadiation therapyBiochemistryInternal medicineIn vitroOxygenCytotoxicityOrganic chemistryNanoplatforms for cancer theranosticsPhotodynamic Therapy Research StudiesAdvanced Nanomaterials in Catalysis
A light and hypoxia-activated nanodrug for cascade photodynamic-chemo cancer therapy | Litcius